{"disease":{"id":"system-sclerosis","name":"system sclerosis"},"drugs":{"marketed":[{"drug_id":"rituxan","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"nintedanib","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ofev","generic_name":"NINTEDANIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2000","mechanism":"Ofev works by blocking enzymes that promote fibrosis and tumor growth."},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Systemic Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"vargatef","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vargatef","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"discontinued","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"benzoic-acid","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzeneformic Acid","generic_name":"benzoic acid","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"bosentan","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tracleer","generic_name":"BOSENTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"orthocaine","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"orthocaine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofev","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OFEV®","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"Kinase Inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"ruxience","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"aminobenzoic-acid","indication_name":"Systemic sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aminobenzoate Potassium","generic_name":"aminobenzoic acid","company_name":"","drug_phase":"unknown","molecular_target":"Carbonic anhydrase 2","drug_class":"Vitamin B Complex Member","quality_score":null,"revenue":null,"mechanism":"Aminobenzoate Potassium works by inhibiting the enzyme carbonic anhydrase 2, which plays a crucial role in maintaining the pH balance in cells."}],"pipeline":[],"offLabel":[],"totalMarketed":29,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT07077304","title":"EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT00794352","title":"Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System","phase":"","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05879419","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2005,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT07080125","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05088473","title":"Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT07000916","title":"Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT06772896","title":"Evaluating the Effect of Questionnaire Context on the Reporting of Somatic Items Among People With Systemic Sclerosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":851,"lead_sponsor_name":"Lady Davis Institute","has_results":false},{"nct_id":"NCT01208792","title":"Auto-immunity and Pulmonary Arterial Hypertension","phase":"NA","overall_status":"COMPLETED","enrollment_count":629,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06596746","title":"Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Casa di Cura San Raffaele Cassino","has_results":false},{"nct_id":"NCT03430388","title":"Yellow Fever Vaccine in Patients With Rheumatic Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT05345795","title":"Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03588845","title":"The Small Intestine Bacterial Overgrowth Study Pilot","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Canadian Scleroderma Research Group","has_results":false},{"nct_id":"NCT07515638","title":"Immun4Cure Cohort of Autoimmune Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT06894654","title":"DERMATOMICS: Identifying Regulators of Skin Homeostasis","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Relation Therapeutics","has_results":false},{"nct_id":"NCT07188285","title":"Mass Spectrometry-based Immune Profiling in Autoimmune Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07087912","title":"Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":477,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT03419208","title":"Scleroderma Patient-centered Intervention Network (SPIN) Hand Program","phase":"NA","overall_status":"COMPLETED","enrollment_count":466,"lead_sponsor_name":"Lady Davis Institute","has_results":false},{"nct_id":"NCT07277491","title":"Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity","phase":"","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT07497087","title":"A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":448,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06029335","title":"Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"University of Pecs","has_results":false},{"nct_id":"NCT04363021","title":"Is a History of Pre-eclampsia a Risk Factor for Vascular Phenotype in Women With Systemic Sclerosis?","phase":"","overall_status":"COMPLETED","enrollment_count":378,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03398837","title":"Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":365,"lead_sponsor_name":"Corbus Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT05925803","title":"Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":314,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04781543","title":"A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":301,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06412614","title":"Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05878717","title":"A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT05168215","title":"Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT05785624","title":"A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":286,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT05869955","title":"A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","has_results":false},{"nct_id":"NCT06462768","title":"Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT05000216","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":258,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05103553","title":"What is the Optimal Follow-up for Patients With Systemic Sclerosis?","phase":"NA","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT07000903","title":"Occupational and Environmental Causes of Autoimmune Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT06308978","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":244,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT04995588","title":"Systemic Sclerosis and Innate T Cells","phase":"NA","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT03543956","title":"Professional and Personal Toxic Exposure in Systemic Sclerosis : Type, Intensity and Probability of Exposition","phase":"","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06732674","title":"Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":218,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT03340194","title":"Evaluation of Calcinosis in Systemic Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT02453256","title":"A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06888973","title":"Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","has_results":false},{"nct_id":"NCT06470048","title":"A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04040322","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Civi Biopharma, Inc.","has_results":true},{"nct_id":"NCT06544343","title":"Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT03268239","title":"Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions","phase":"NA","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT05626751","title":"An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":174,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04335279","title":"Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","phase":"NA","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"Lady Davis Institute","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}